This document corrects and replaces the press release that was issued by Kali Inc. (OTC Pink: KALY) (“KALY”) today July 16, 2020 at 11:24 am ET. The release below replaces the entirety of the previous release, as the incorrect release was sent. The corrected press release follows in full below: Dallas, Texas--(Newsfile Corp. - July 16, 2020) - Kali, Inc. (OTC Pink: KALY) ("KALY") today announced a deal in the works to sell its cannabis execration subsidiary, NCM Biotech, to PAO Group, Inc....
Dallas, Texas--(Newsfile Corp. - July 16, 2020) - Kali-Extracts, Inc. (OTC Pink: KALY) (Kali, Inc. dba/Kali-Extracts, Inc.) ("KALY") today issued a call for potential partners that could contribute to the acceleration of evaluating and developing KALY's proprietary CBD formulation developed for the treatment of symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. Researchers believe the CBD formulation could be effective in the treatment...
Dallas, Texas--(Newsfile Corp. - February 3, 2020) - Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (OTC Pink: KALY) ("KALY"), today previewed a Letter of Intent (LOI) executed with a third-party investor. The LOI details are anticipated to be released tomorrow. Management indicates the two-stage investment is of substantial magnitude and can meaningfully advance the company's ongoing development of its cannabis biopharmaceutical technology. KALY has a U.S. Patented Cannabis Extraction...
Dallas, Texas--(Newsfile Corp. - January 31, 2020) - Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (OTC Pink: KALY) ("KALY") today pointed to a Grand View Research report on the legal marijuana market projecting the legal marijuana market to reach over $66 Billion in value by 2025 to support a recent $50 Million valuation of KALY's cannabis biotechnology. KALY has U.S. Patented Cannabis Extraction Process it uses to produce proprietary formulations for the treatment of various medical...
Dallas, Texas--(Newsfile Corp. - January 29, 2020) - Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (OTC Pink: KALY) ("KALY") today confirmed efforts to evaluate its proprietary CBD extract formulation as a treatment for coronavirus symptoms. KALY's proprietary CBD formulation has been developed for the treatment of symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions . The formulation for the treatment of symptoms associated...
Dallas, Texas--(Newsfile Corp. - January 24, 2020) - Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (OTC Pink: KALY) ("KALY") today announced entering negotiations on the spinoff of the company's agricultural CBD extraction business. The spinoff is part of KALY's plans to consolidate its business structure and focus on its Cannabis Biopharmaceutical Technology. KALY has a U.S. Patented Cannabis Extraction Process and is developing treatments for various medical conditions. The...
Dallas, Texas--(Newsfile Corp. - January 14, 2020) - Kali-Extracts, Inc. (OTC Pink: KALY) (Kali, Inc. dba/Kali-Extracts, Inc.) ("KALY") today announced plans to consolidate its business structure and focus on its Cannabis Biopharmaceutical Technology. KALY has a U.S. Patented Cannabis Extraction Process and is developing treatments for various medical conditions. The technology has been valued at $50 million in conjunction with a recent acquisition offer that ALYI management passed on. In...
Dallas, Texas--(Newsfile Corp. - January 8, 2020) - Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (OTC Pink: KALY) ("KALY") today announced that management will release its 2020 Cannabis Biopharmaceutical Technology Strategy next week on Tuesday, January 14, 2020. KALY has a U.S. Patented Cannabis Extraction Process and is developing treatments for various medical conditions. After receiving two inquiries into the acquisition of the company's cannabis biopharmaceutical technology...
Dallas, Texas--(Newsfile Corp. - December 23, 2019) - Kali-Extracts, Inc. (OTC Pink: KALY) (Kali, Inc. dba/Kali-Extracts, Inc.) ("KALY") today announced that the Company has reached $1 million in sales. Subject to an accounting review of its overall 2019 financials, management anticipates reporting over $1 million in revenue for 2019. The major revenue contribution comes from KALY's first hemp extraction contracts. KALY's revenues through the end of Q3 come primarily from the sale of CBD infused...
Dallas, Texas--(Newsfile Corp. - December 17, 2019) - Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (OTC Pink: KALY) ("KALY") today announced an anchor investor in its biopharmaceutical technology. KALY recently announced restructuring its cannabis biopharmaceutical business as part of a strategy to facilitate a strategic investment at a $50 million valuation. KALY has a U.S. Patented Cannabis Extraction Process and is developing treatments for various medical conditions (see below)....
Dallas, Texas--(Newsfile Corp. - December 11, 2019) - Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (OTC Pink: KALY) ("KALY") today announced expected revenue growth acceleration in 2020 from the sales of CBD infused consumer products. The company currently generates revenue from the sale of CBD infused candies and beverages. KALY produces and sells Hemp4mula chewing gum and gummies available on www.USMJ.com and it has licensed its patented cannabis extraction process for the...
Dallas, Texas--(Newsfile Corp. - December 10, 2019) - Kali-Extracts, Inc. (OTC Pink: KALY) (Kali, Inc. dba/Kali-Extracts, Inc.) ("KALY") today announced the company is restructuring its cannabis biopharmaceutical business. KALY has a U.S. Patented Cannabis Extraction Process and is developing treatments for various medical conditions (see below). KALY has recently announced receiving two inquiries into the acquisition of the company's cannabis biopharmaceutical technology valuing the technology...
Dallas, Texas--(Newsfile Corp. - December 6, 2019) - Kali-Extracts, Inc. (OTC Pink: KALY) (Kali, Inc. dba/Kali-Extracts, Inc.) ("KALY") today announced it will proceed with a capital infusion plan to accelerate the growth of its cannabis biopharmaceutical technology. KALY has recently announced receiving two inquiries into the acquisition of the company's cannabis biopharmaceutical technology valuing the technology at $50 million. KALY has a U.S. Patented Cannabis Extraction Process and is...
DALLAS, Nov. 29, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced that it anticipates reaching $1 million in revenue by year end 2019 with the contribution of its first hemp extraction contracts being realized in the fourth quarter of 2019. Earlier this week, the company published a financial performance update in conjunction with KALY’s financial performance report through September 30, 2019....
DALLAS, Nov. 27, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today confirmed that it has the potential to reach $1 million in revenue by year end 2019. The company yesterday published a financial performance update in conjunction with KALY’s financial performance report through September 30, 2019. KALY’s current revenues come primarily from the sale of CBD infused products that have utilized KALY’s U.S....
DALLAS, Nov. 25, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced a management financial performance update scheduled for release tomorrow, November 26, 2019. The update will be published in conjunction with KALY’s financial performance report through September 30, 2019. Management will highlight the company’s growing sales and underlying asset value. Management intends to specifically highlight...
DALLAS, Nov. 21, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today confirmed introducing a third option to compete with the two acquisition offers currently being entertained by KALY management. KALY has recently announced receiving two inquiries into the acquisition of the company’s cannabis biopharmaceutical technology valuing the technology at $50 million. KALY management is entertaining the inquiries but...
DALLAS, Nov. 20, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced introducing a third option to compete with the two acquisition offers currently being entertained by KALY management. KALY has recently announced receiving two inquiries into the acquisition of the company’s cannabis biopharmaceutical technology valuing the technology at $50 million. KALY management is entertaining the inquiries but...
DALLAS, Nov. 14, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today highlighted GW Pharmaceuticals $3.5 Billion market capitalization. GW Pharma’s cannabis biopharmaceutical technology is featured today in a ZACHS Investment Research article . KALY has a U.S. Patented Cannabis Extraction Process and is developing treatments for various medical conditions (see below). Doctors working with KALY on the treatment...
DALLAS, Nov. 12, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today confirmed a second party has approached the company to express interest in acquiring KALY’s U.S. Patented Cannabis Extraction Process and related biopharmaceutical technology valued at $50 million. KALY recently announced entering into discussions with a first investor to explore a possible sale of KALY’s cannabis biopharmaceutical technology....
